Scancell secures Australian patent
3rd Sep 2013 14:13
Scancell said it had received a patent for its DNA ImmunoBody treatment in Australia. Australia is the first jurisdiction to approve the DNA patent. Scancell said it was an important step to comprehensively protecting the technology. Scancell specialises in treatments to encourage the immune sys
Read moreSABMilller Chairman sells over 11m pounds in shares
23rd Jul 2013 16:21
Graham Mackay, the Chairman of SABMiller who is currently on a medical leave of absence due to a brain tumour, has sold over 11m pounds-worth of shares in the company. Mackay sold a total of 350,000 shares between July 16-18th through three separate transactions, the firm revealed on Tuesday. He so
Read moreScancell shares healthy following patent approval award in Japan
6th Feb 2013 11:06
Shares in cancer vaccine developer Scancell rose on Wednesday after the company announced its ImmunoBody Patent had been approved in Japan. The same patent has already been approved in the US, Europe and Australia. Dr Richard Goodfellow, Joint Chief Executive Officer of Scancell, commented: "This
Read moreSector movers: Pharmaceuticals under the weather as AstraZeneca takes a hit
31st Jan 2013 15:04
The pharmaceuticals and biotechnology sector was at the bottom of the pile on Thursday after a disappointing set of full-year results from AstraZeneca weighed on share prices. The company, which manufactures drugs to treat range of cardiovascular conditions, reported a 15% fall in revenue at consta
Read moreSix month operating loss increases slightly at Scancell
31st Jan 2013 14:33
AIM-listed medical company Scancell has published its unaudited interim results for the six month period to October 31st, showing an overall operating loss of 989,981 pounds. This compared to a loss of £941,674 in the corresponding period in 2011. The cash at bank on October 31st was £2.6m compar
Read moreScancell Holdings updates on clinical trial of melanoma vaccine
29th Jan 2013 09:05
Scancell Holdings said Tuesday it edged closer to completing clinical trials of a vaccine for the treatment of melanoma. The developer of therapeutic cancer vaccines recruited and treated the final patient in the second phase of tests for SCIB1, a DNA ImmunoBody injection. The trial is being cond
Read more